Background: Small heat shock proteins are molecular chaperones that protect proteins against stress-induced aggregation. They have also been found to have anti-apoptotic activity and to play a part in the development of tumors. Recently, we identified a new small heat shock protein, Hsp16.2 which displayed increased expression in neuroectodermal tumors. Our aim was to investigate the expression of Hsp16.2 in different types of brain tumors and to correlate its expression with the histological grade of the tumor.
Background
Most malignant neoplasms in the brain already carry a dismal prognosis when they are diagnosed. Therefore, the treatment of human brain tumors possesses a continuous challenge for oncological research. Although several brain tumor markers have been studied as possible prognostic factors, further study is needed to reveal the complex mechanism of tumor genesis, thus helping to discover the most appropriate tumor markers for prognosticating the neoplasm.
Small heat shock proteins have been noted for their possible role in the development of tumors [1, 2] . Functionally these proteins are molecular chaperones that prevent the stress induced aggregation of denatured proteins, thus protecting protein function and activity [3, 4] . Furthermore, sHSPs have anti-apoptotic activity, which -if overexpressed in tumor cells -could lead to increased tumor growth, a resistance to chemo-or radiotherapy and to the unfortunate outcome of the disease [5] [6] [7] [8] .
Previously we identified and characterized a novel small heat shock protein (Hsp16.2) [9] . Overexpression of Hsp16.2 protected cells against various stress stimuli (e.g. hydrogen peroxide, taxol) by the stabilization of the mitochondrial membrane system and the inhibition of caspase 3 activation. It was also demonstrated that the anti-apoptotic effect of Hsp16.2 is mediated by the activation of Hsp90, with which Hsp16.2 binds, and by the activation of the PI-3 kinase-Akt pathway. Furthermore, overexpression of Hsp16.2 increased lipid rafts formation, thus helping to stabilize the plasma membrane [9, 10] .
Preliminary studies indicated that Hsp16.2 is expressed in neuroectodermal tumors [9] . In the present paper we study the different types of brain tumors including benign and malignant meningeoma, oligodendroglioma, glioblastoma multiforme, ependymoma and medulloblastoma. Using immunohistochemistry method and Western blot analysis we determined the expression of Hsp16.2 and its intracellular localization in the tumor cells. Our aim was to examine whether the level of Hsp16.2 expression correlates with the malignancy of the brain tumor. This study provides evidence for the role of Hsp16.2 as a possible marker for brain tumors.
Methods

Tumor materials
Brain tumor samples from ninety-one patients were available for examination. All tumor tissue specimens were provided by the Medical University of Pécs, Department of Neurosurgery and Pathology. Full ethical approval was given by the Regional Research Ethics Committee of the Medical Center of Pécs (Approval Number: 030630). for the use of these samples. Each type of tumor was identified according to the revised WHO classification of Histological Typing of the Tumors of the Central Nervous System (2007) [11] .
Preparation of polyclonal antibodies against Hsp16.2 Rabbits were immunized subcutaneously at multiple sites with 100 pg of recombinant Hsp16.2/GST fusion protein which was expressed as it was described before [9, 10] in Freund's complete adjuvant. Four subsequent booster injections at 4-week intervals were given with 50 pg of protein in Freund's incomplete adjuvant. Blood was collected 10 days after boosting, and the antiserums were stored at -20 C. IgGs were affinity purified from sera by protein G-Sepharose chromatography according to the manufacturer's protocol.
Immunohistochemistry
Sections from the tumor tissue samples were formalinfixed and paraffin-embedded. Subsequently, they were incubated with polyclonal anti-Hsp16.2 polyclonal antibody. Immunohistochemical staining was carried out according to the streptavidin-biotin-peroxidase method with hydrogen peroxide/3-amino-9-ethylcarbazole development using the Universal kit. Only secondary IgG was incubated with the control sections. The evaluation of the slides was done with the help of an Olympus BX50 light microscope with incorporated photography system (Olympus Optical Co., Hamburg, Germany). Both the presence and localization of positive staining for Hsp16.2 was examined. Staining intensity was recorded semiquantitatively as mild (+), moderate (++) or strong (+++), following as it was described before [12] . For internal positive control, the normal cerebral and vascular structures of the samples were used. Positive areas around necrotic fields were excluded due to their probable stress related up-regulation.
Immunoblot analysis
Tumor tissue specimens were homogenized in chilled lysis buffer of 0,5 mM sodium metavanadate, 1 mM EDTA, and protease inhibitor mixture in phosphate-buffered saline in a Teflon/glass homogenizer, and centrifuged. Isolation of cytosol and nuclear fractions were carried out by standard lab protocols exactly as previously [13] . The samples were equalized to 1 mg/ml total protein concentration using Biuret's method and subjected to SDS-PAGE. Proteins (20 μg/lane) were separated on 15% gels and then transferred to nitrocellulose membranes. The membranes were blocked in 5% low fat milk for 1 h at room temperature, then exposed to the primary antiHsp16,2 antibodies at 4°C overnight at a dilution of 1:2,000 in blocking solution. Appropriate horseradish peroxidase-conjugated secondary antibodies were used for 2 h at room temperature and at 1:5,000 dilution. Peroxidase labeling was visualized with enhanced chemilu-minescence (ECL) using an ECL Western blotting detection system (Amersham Biosciences). The developed films were scanned, and the pixel volumes of the bands were determined using NIH Image J software. All experiments were repeated four times.
Statistical analysis
Difference in distribution of variables between groups was tested using χ 2 test. Values of p < 0.01 were considered to be significant.
Results
Expression and intracellular localization of Hsp16.2 in different brain tumors by immunohistochemistry
Ninety-one samples of different brain tumors were evaluated in the present study (Table 1) Hsp16.2 immunoreactivity was found both in the nucleus and in some cases in the cytoplasm in tumor tissues (Fig.  1 ). Since intranuclear labeling was present in all tumor samples in large quantities, cytoplasmic Hsp16.2 immunoreactivity could be used for differential diagnostic purposes. Cytoplasmic labeling varied considerably among the different histological types and grades of tumors. Low grade tumors (grades 1-2) showed weak or no staining (+/-) in the cytoplasm (Fig. 1.A,B) . There was no detectable Hsp16.2 in the cytoplasm of the benign schwannoma ( Fig. 1.A) and one pilocytic- (Fig 1.B) and two diffuse astrocytomas. The remaining low grade tumors stained weakly (Fig. 1.C,E), excepting ependymomas (Fig. 1.G) and atypical meningeomas, which stained moderately (++).
Grade 3 tumors, including malignant meningeomas (Fig.  1.F) , anaplastic astrocytomas (Fig 1.D) and oligodendrogliomas ( Fig. 1.H (Fig. 1.I) , medulloblastomas and PNETs (Fig. 1.J) 
Detection of Hsp16.2 expression by Western-blot
After subcellular fractionation, the expression of Hsp16.2 was determined from both the cytosolic (Fig. 2) 7) . The strongest bands appeared in the cytoplasmic samples of medulloblastomas, PNETs and glioblastomas (8) (9) (10) . In conclusion, the observed Hsp16.2 labeling correlated with the results gained by the immunohistochemistry method.
Discussion
Small stress proteins are a group of heat shock proteins that share an evolutionary conserved C-terminal region, called the alpha-crystallin domain, and whose molecular weight ranges between 15 and 43 kDas [1, 7, [14] [15] [16] . They are known to play a part in cell differentiation and in counteracting apoptosis [7] . Due to the anti-apoptotic activity of sHsps, tumor cells expressing the protein highly may become increasingly resistant to chemo-or radiotherapy [1, [17] [18] [19] .
A number of recent studies have been concerned with the possible role of small heat shock proteins in the progression of brain tumors. Aoyama et al. reported increased expression of alphaB-crystallin in human glial tumors such as astrocytomas and glioblastoma multiforme [20] . Astrocytic neoplasms were examined for Hsp27 immunoreactivity also. While normal astrocytes showed no Hsp27 immunoreactivity, low Hsp27 expression was found in benign astrocytomas and elevated levels of Hsp27 found in poorly differentiated tumors. There are data indicating the direct correlation between Hsp27 expression and the histologic grade of astrocytic tumors [17, [21] [22] [23] . The prognostic significance of Hsp27, Hsp 70, and Hsp90 in medulloblastomas was examined with equivocally positive results [24] .
Previously, we reported the existence of a novel small stress protein, sHsp16.2 and its high levels of expression in neuroectodermal cancers [9] . This finding turned our According to our findings, Hsp16.2 could be a marker whose cytoplasmic expression increases as the tumor progresses. The cytoplasmic expression of the protein correlates directly with the grade of the tumors, it is only present in tumor cells in significant quantity and its level increases with the increase of cell anaplasia.
Conclusion
We have found that the Hsp16.2 could become a valuable marker for primary brain tumor diagnosis and the antiapoptotic activity of sHsp16.2 could become the target of drug therapy. Still, further efforts need to be made to reveal the exact role and function of sHsp16.2 in tumor cells. However, the significance of this novel small stress protein in anti-cancer research seems certain.
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